These cells not only suppress T cell function through direct interactions but also secrete immunosuppressive and pro‐angiogenic mediators, including TYMP and TGFB, which further reinforce immune evasion and tumor progression.[42, 43, 44] Given this context, ICIs monotherapy may be insufficient to mount effective antitumor immunity. The gene discussed is TGFB1; the disease is neoplasm.